A global database of COVID-19 vaccinations.


Journal

Nature human behaviour
ISSN: 2397-3374
Titre abrégé: Nat Hum Behav
Pays: England
ID NLM: 101697750

Informations de publication

Date de publication:
07 2021
Historique:
received: 18 03 2021
accepted: 21 04 2021
pubmed: 12 5 2021
medline: 5 8 2021
entrez: 11 5 2021
Statut: ppublish

Résumé

An effective rollout of vaccinations against COVID-19 offers the most promising prospect of bringing the pandemic to an end. We present the Our World in Data COVID-19 vaccination dataset, a global public dataset that tracks the scale and rate of the vaccine rollout across the world. This dataset is updated regularly and includes data on the total number of vaccinations administered, first and second doses administered, daily vaccination rates and population-adjusted coverage for all countries for which data are available (169 countries as of 7 April 2021). It will be maintained as the global vaccination campaign continues to progress. This resource aids policymakers and researchers in understanding the rate of current and potential vaccine rollout; the interactions with non-vaccination policy responses; the potential impact of vaccinations on pandemic outcomes such as transmission, morbidity and mortality; and global inequalities in vaccine access.

Identifiants

pubmed: 33972767
doi: 10.1038/s41562-021-01122-8
pii: 10.1038/s41562-021-01122-8
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

947-953

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (Johns Hopkins University, accessed 7 April 2021); https://arcg.is/0fHmTX
Hale, T. et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat. Hum. Behav. 5, 529–538 (2021).
doi: 10.1038/s41562-021-01079-8
Hasell, J. et al. A cross-country database of COVID-19 testing. Sci. Data. 7, 345 (2020).
doi: 10.1038/s41597-020-00688-8
Kim, J. H., Marks, F. & Clemens, J. D. Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med. 27, 205–211 (2021).
doi: 10.1038/s41591-021-01230-y
Sachs, J. et al. Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. Lancet 397, 947–950 (2021).
doi: 10.1016/S0140-6736(21)00388-3
Rosen, B., Waitzberg, R. & Israeli, A. Israel’s rapid rollout of vaccinations for COVID-19. Isr. J. Health Policy Res. 10, 6 (2021).
doi: 10.1186/s13584-021-00440-6
Lee, T. H. & Chen, A. H. Last-mile logistics of Covid vaccination—the role of health care organizations. New Engl. J. Med. 384, 685–687 (2021).
doi: 10.1056/NEJMp2100574
Cylus, J., Panteli, D. & Van Ginneken, E. Who should be vaccinated first? Comparing vaccine prioritization strategies in Israel and European countries using the Covid-19 Health System Response Monitor. Isr. J. Health Policy Res. 10, 16 (2021).
doi: 10.1186/s13584-021-00453-1
Shrotri, M., Swinnen, T., Kampmann, B. & Parker, E. P. K. An interactive website tracking COVID-19 vaccine development. Lancet Glob. Health 9, 590–592 (2021).
doi: 10.1016/S2214-109X(21)00043-7
Alkandari, D., Herbert, J. A., Alkhalaf, M. A., Yates, C. & Panagiotou, S. SARS-CoV-2 vaccines: fast track versus efficacy. Lancet Microbe 2, e89–e90 (2021).
doi: 10.1016/S2666-5247(21)00034-3
Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New Engl. J. Med. 384, 1412–1423 (2021).
doi: 10.1056/NEJMoa2101765
Ramos, A. M., Vela-Perez, M., Ferrandez, M. R., Kubik, A. B. & Ivorra, B. Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19. Preprint at ResearchGate.net https://doi.org/10.13140/RG.2.2.32580.24967/2 (2021).
Iacobucci, G. & Mahase, E. Covid-19 vaccination: what’s the evidence for extending the dosing interval? BMJ 372, 18 (2021).
doi: 10.1136/bmj.n18
Mahase, E. Covid-19: medical community split over vaccine interval policy as WHO recommends six weeks. BMJ 372, 226 (2021).
doi: 10.1136/bmj.n226
Baraniuk, C. Covid-19: how the UK vaccine rollout delivered success, so far. BMJ 372, 421 (2021).
doi: 10.1136/bmj.n421
Vanderslott, S., Dadonaite, B. & Roser, M. Vaccination. OurWorldinData.org https://ourworldindata.org/vaccination (2013).
Verger, P. & Dubé, E. Expert review of vaccines restoring confidence in vaccines in the COVID-19 era. Expert Rev. Vaccines 19, 991–994 (2020).
doi: 10.1080/14760584.2020.1825945
Kreps, S. et al. Factors associated with US adults’ likelihood of accepting COVID-19 vaccination. JAMA Netw. Open 3, e2025594 (2020).
doi: 10.1001/jamanetworkopen.2020.25594
Sherman, S. M. et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Hum. Vaccin. Immunother. https://doi.org/10.1080/21645515.2020.1846397 (2020).
Population Dynamics. World Population Prospects: The 2019 Revision, DVD Edn (United Nations, Department of Economic and Social Affairs, 2019).

Auteurs

Edouard Mathieu (E)

Our World in Data.

Hannah Ritchie (H)

Our World in Data, . hannah.ritchie@oxfordmartin.ox.ac.uk.
Oxford Martin Programme on Global Development, University of Oxford, Oxford, United Kingdom. hannah.ritchie@oxfordmartin.ox.ac.uk.

Esteban Ortiz-Ospina (E)

Our World in Data.
Oxford Martin Programme on Global Development, University of Oxford, Oxford, United Kingdom.

Max Roser (M)

Our World in Data.
Oxford Martin Programme on Global Development, University of Oxford, Oxford, United Kingdom.

Joe Hasell (J)

Our World in Data.
Oxford Martin Programme on Global Development, University of Oxford, Oxford, United Kingdom.
Department of Social Policy and Intervention, University of Oxford, Oxford, United Kingdom.

Cameron Appel (C)

Our World in Data.

Charlie Giattino (C)

Our World in Data.
Oxford Martin Programme on Global Development, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH